Summary
Every year, the pharma and food industries lose € 43 billion-worth of medicinal and nutritional products due to failures in cold chain logistics. Cold chain logistics is a complex network, where real-time tracking and monitoring of products is the only way to quickly identify failures and minimise losses. Manufacturers, such as pharma companies, who’s products are lost, are thus leading the push towards optimisation of tracking and tracing practices in cold chain logistics. But how can this be done? Temperature-sensitive sensor technologies, such as stick-on tracker tags, have the potential to reduce waste generated in cold-chain logistics by 5-7%, as temperature problems in the cold chain can be quickly identified and rectified. Today, this instant identification is only possible with so called semi-passive tags, which allow for real-time tracking of temperature-sensitive products. They are however very expensive, costing up to €18/tag. This means that for low-value products, where profit margins cannot cover the cost of these expensive tags, no optimisation of the logistics cold-chain and thus wastage prevention can occur. At Myruns, we have developed the first semi-passive stick-on tag, Tag&Go, at a 96% lower price than existing semi-passive solutions. Tag&Go is made possible through an optimised and patented processing route. Tag&Go simply “drops-in” to customer processes and enables real-time monitoring by any relevant party, such as product manufacturers, logistics providers or customers. Therefore, any failures in the logistics cold-chain can be identified instantly and cheaply, and rectified. €3 billion can be saved by preventing product damage through optimised cold chain logistics practices, and Tag&Go is a key enabler of this saving. Tag&Go has thus already received significant interest from the cold-chain-dependent pharma industry. We therefore expect to capture 2.2% of the European SAM by 2026, creating 60 new jobs in the process.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/876386 |
| Start date: | 01-07-2019 |
| End date: | 30-09-2019 |
| Total budget - Public funding: | 71 429,00 Euro - 50 000,00 Euro |
Cordis data
Original description
Every year, the pharma and food industries lose € 43 billion-worth of medicinal and nutritional products due to failures in cold chain logistics. Cold chain logistics is a complex network, where real-time tracking and monitoring of products is the only way to quickly identify failures and minimise losses. Manufacturers, such as pharma companies, who’s products are lost, are thus leading the push towards optimisation of tracking and tracing practices in cold chain logistics. But how can this be done? Temperature-sensitive sensor technologies, such as stick-on tracker tags, have the potential to reduce waste generated in cold-chain logistics by 5-7%, as temperature problems in the cold chain can be quickly identified and rectified. Today, this instant identification is only possible with so called semi-passive tags, which allow for real-time tracking of temperature-sensitive products. They are however very expensive, costing up to €18/tag. This means that for low-value products, where profit margins cannot cover the cost of these expensive tags, no optimisation of the logistics cold-chain and thus wastage prevention can occur. At Myruns, we have developed the first semi-passive stick-on tag, Tag&Go, at a 96% lower price than existing semi-passive solutions. Tag&Go is made possible through an optimised and patented processing route. Tag&Go simply “drops-in” to customer processes and enables real-time monitoring by any relevant party, such as product manufacturers, logistics providers or customers. Therefore, any failures in the logistics cold-chain can be identified instantly and cheaply, and rectified. €3 billion can be saved by preventing product damage through optimised cold chain logistics practices, and Tag&Go is a key enabler of this saving. Tag&Go has thus already received significant interest from the cold-chain-dependent pharma industry. We therefore expect to capture 2.2% of the European SAM by 2026, creating 60 new jobs in the process.Status
CLOSEDCall topic
EIC-SMEInst-2018-2020Update Date
27-10-2022
Images
No images available.
Geographical location(s)
Search
